VYNE Therapeutics Inc. reported its financial results for the third quarter of 2025, revealing a total revenue of $169,000, a 39.7% increase from $121,000 in the same period last year. The company’s royalty revenues from its agreement with LEO Pharma rose to $440,000 for the nine months ended September 30, 2025, compared to $417,000 for the same period in 2024. Despite this increase in revenue, VYNE continued to experience significant operating losses, reporting a net loss of $7.3 million for the quarter, down from a loss of $12.2 million in the prior year, reflecting a 40.1% improvement.
Operating expenses for the third quarter decreased to $7.96 million, a reduction of 39.7% compared to $13.2 million in the same quarter of 2024. This decline was primarily driven by a significant reduction in research and development expenses, which fell to $5.26 million from $10.25 million year-over-year. The decrease in R&D spending was attributed to the timing of expenses related to the Phase 2b trial of repibresib and the Phase 1 trials for VYN202, as well as the decision to terminate the vitiligo trial after it did not meet its primary endpoint.
In terms of strategic developments, VYNE has been focusing on its immuno-inflammatory pipeline, particularly the development of VYN202, a BD2-selective BET inhibitor. The company has initiated a strategic review to explore options for maximizing shareholder value, which may include partnerships, licensing opportunities, or potential mergers and acquisitions. Additionally, VYNE has implemented cost reductions to extend its cash runway, which is projected to last into the first half of 2027.
As of September 30, 2025, VYNE had cash, cash equivalents, and marketable securities totaling $32.7 million, with an accumulated deficit of $752.8 million. The company reported using $29.4 million in cash for operations during the first nine months of 2025, compared to $25 million in the same period of 2024. VYNE has no outstanding debt and is actively seeking additional capital to fund its operations and product development, as it does not expect to generate significant revenue until its product candidates receive regulatory approval.
Looking ahead, VYNE's management remains cautious about the macroeconomic environment, which includes inflation and market volatility that could impact its ability to raise capital. The company is focused on executing its business strategy and advancing its product candidates, while also navigating the challenges posed by the current economic landscape.
About VYNE Therapeutics Inc.
VYNE Therapeutics Inc. is a clinical-stage biopharmaceutical company developing therapies for immune-mediated inflammatory conditions. Its core platform involves small molecule BET inhibitors, targeting epigenetic regulators of inflammation. Key products include topical repibresib gel for vitiligo and oral VYN202 for autoimmune diseases like psoriasis. The company focuses on localized, low systemic exposure treatments, leveraging proprietary compounds and licensing agreements to address high unmet medical needs.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.